Australia unveiled a major investment to advance brain cancer clinical research, spotlighting landmark immunotherapy breakthroughs and patient-focused innovation
Australia unveiled a major investment to advance brain cancer clinical research, spotlighting landmark immunotherapy breakthroughs and patient-focused innovation
New data reveals that smaller biopharma players are gaining ground in innovation, contributing a growing share of first-in-class …
Prime Minister Starmer unveils ambitious reforms to speed up trial timelines and centralize NHS data, aiming to restore …
Early-stage data reveal tumour targeting and tolerability with radiolabelled GRPR antagonist therapy in metastatic prostate cancer
MaaT Pharma advances its microbiome ecosystem therapies with new preclinical evidence showing enhanced patient immunotherapy responses.
Experimental gene-silencing drug lepodisiran delivers long-lasting reduction of cardiovascular risk factor, while Spinogenix launches trial for novel synaptic …
The sudden departure of FDA’s Peter Marks raises uncertainty across the biopharma sector amid ongoing regulatory scrutiny and …
MaaT Pharma strengthens financial position to advance its microbiome-based therapies, focusing on acute graft-versus-host disease and hemato-oncology indications.
Long-term clinical data from Roche strengthen the case for disease-modifying therapies in spinal muscular atrophy and Duchenne muscular …
Promising clinical results highlight Gilead’s innovative approach to long-acting HIV treatment, aiming to improve patient adherence and outcomes.
Already a subscriber? Log in